Synthetic Biologics, Inc. announced that it has entered into a securities purchase agreement for the private placement of 275,000 Series C convertible preferred shares and 100,000 Series D convertible preferred shares at a price of $8 per share for gross proceeds of approximately $3 million with returning investor MSD Credit Opportunity Master Fund, L.P., a fund managed by MSD Partners, L.P. on July 28, 2022. The Series C convertible preferred shares and Series D convertible preferred shares have a conversion price of $1.22. The securities are subject to transfer restrictions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2431 USD | +2.53% |
|
-0.86% | -43.48% |
05-23 | Theriva Biologics Gets Fast Track Designation for Pancreatic Cancer Treatment | MT |
05-23 | Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.48% | 4.2M | |
+16.13% | 122B | |
+19.65% | 113B | |
+20.35% | 26.49B | |
-23.84% | 19.4B | |
-17.68% | 16.24B | |
-45.95% | 15.15B | |
-19.28% | 15.4B | |
+63.81% | 14.93B | |
+1.94% | 13.52B |
- Stock Market
- Equities
- TOVX Stock
- News Theriva Biologics, Inc.
- Theriva Biologics, Inc. announced that it expects to receive $3 million in funding from MSD Partners, L.P.